Metabolic Health Digest
Efficacy and safety of once-weekly Efpeglenatide vs. Placebo as monotherapy in patients with type 2 diabetes (AMPLITUDE-M)
Efpeglenatide is being subcutaneously administered once per week as a long-acting GLP-1 receptor agonist. Frias JP and colleagues conducted a study under the title...
Efficacy and safety of once-weekly Tirzepatide, a dual GIP/GLP-1 receptor agonist vs. placebo as monotherapy in people with type 2 diabetes (SURPASS-1)
With the increasing prevalence of diabetes, new treatment approaches are in need of time. Rosenstock J and colleagues conducted research under the title “Efficacy...
Fibrocalculous Pancreatic Diabetes: (FCPD)
A most common form of diabetes worldwide is Type 1 and Type 2 diabetes. Fibrocalculous pancreatic diabetes (FCPD) is a unique form of diabetes,...